^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    12d
    A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jul 2027 --> Mar 2027
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    14d
    A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] (clinicaltrials.gov)
    P2, N=140, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine
    15d
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=22, Completed, Chugai Pharmaceutical | Active, not recruiting --> Completed | N=231 --> 22 | Trial completion date: Oct 2029 --> Jan 2026 | Trial primary completion date: Oct 2029 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN6 (Claudin 6)
    |
    SAIL66
    15d
    A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (clinicaltrials.gov)
    P2, N=110, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine
    19d
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    22d
    BP41072: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=498, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)
    27d
    Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) (clinicaltrials.gov)
    P2, N=180, Recruiting, I-Mab Biopharma US Limited
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • CLDN18.2 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • givastomig (TJ-CD4B)
    28d
    YH32367-101: Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor (clinicaltrials.gov)
    P1/2, N=147, Recruiting, Yuhan Corporation | Trial completion date: Dec 2026 --> Apr 2028 | Trial primary completion date: Oct 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    cisplatin • nesfrotamig (ABL105)
    1m
    Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. (PubMed, Cancer Res Commun)
    This open-label, 4-part, phase 1 study evaluated INBRX-105 alone or with pembrolizumab in adults with locally advanced/metastatic, unresectable solid tumors (NCT03809624). Unfortunately, clinical development of INBRX-105 was ended because of hepatotoxicity and limited efficacy. Novel treatment combinations with nonredundant, complementary immunotherapies are needed.
    P1 data • Journal • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    1m
    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Cabaletta Bio | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV
    1m
    STA101JG: A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours (2023-508764-30-00)
    P1, N=30, Active, not recruiting, Chugai Pharmaceutical Co. Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P1
    Enrollment closed • Phase classification
    |
    Tecentriq (atezolizumab) • STA551
    1m
    RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P2/3, N=74, Recruiting, Cabaletta Bio | Phase classification: P1/2 --> P2/3 | N=24 --> 74
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV